

Dorothee Oberdhan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7676661/publications.pdf>

Version: 2024-02-01

23
papers

349
citations

1040056

9
h-index

839539

18
g-index

23
all docs

23
docs citations

23
times ranked

415
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Polycystic Kidney Diseaseâ€“Related Disease Burden in Adolescents With Autosomal Dominant Polycystic Kidney Disease: An International Qualitative Study. <i>Kidney Medicine</i> , 2022, 4, 100415. | 2.0 | 7 |
| 2 | Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD. <i>Kidney International Reports</i> , 2022, 7, 1037-1048. | 0.8 | 6 |
| 3 | Developing a Conceptual Disease Model of Patient Experiences and Identifying Patient-Reported Clinical Outcome Assessments for Use in Trials of Treatments for Focal Onset Seizures. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 611-631. | 2.2 | 0 |
| 4 | Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€“Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2021, 77, 255-263. | 1.9 | 21 |
| 5 | Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage. <i>Journal of Medical Economics</i> , 2021, 24, 193-201. | 2.1 | 1 |
| 6 | Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey Study. <i>International Journal of Nephrology and Renovascular Disease</i> , 2021, Volume 14, 105-115. | 1.8 | 4 |
| 7 | A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD. <i>Kidney International Reports</i> , 2020, 5, 790-800. | 0.8 | 6 |
| 8 | <p>Review of Clinical Outcome Assessments in Pediatric Attention-Deficit/Hyperactivity Disorder</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 1619-1643. | 2.2 | 10 |
| 9 | The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations. <i>Kidney International Reports</i> , 2020, 5, 801-812. | 0.8 | 16 |
| 10 | The societal economic burden of autosomal dominant polycystic kidney disease in the United States. <i>BMC Health Services Research</i> , 2020, 20, 126. | 2.2 | 26 |
| 11 | PUK10 SOCIETAL BURDEN OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) IN THE UNITED STATES: BEYOND HEALTHCARE COSTS. <i>Value in Health</i> , 2019, 22, S382. | 0.3 | 0 |
| 12 | Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimerâ€™s Disease Interventions. <i>Pharmacoeconomics</i> , 2019, 37, 597-608. | 3.3 | 46 |
| 13 | Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. <i>American Journal of Kidney Diseases</i> , 2018, 71, 225-235. | 1.9 | 36 |
| 14 | Health-Related Quality of Life (HRQOL) in Adolescents with Autosomal Dominant Polycystic Kidney Disease (ADPKD). <i>Value in Health</i> , 2018, 21, S114-S115. | 0.3 | 0 |
| 15 | Impact of Autosomal Dominant Polycystic Kidney Disease (ADPKD) on Caregivers and Families. <i>Value in Health</i> , 2018, 21, S109-S110. | 0.3 | 1 |
| 16 | [P4â€™557]: FAMILY AND CAREGIVER SPILLOVER EFFECTS IN ALZHEIMER'S DISEASE COSTâ€™EFFECTIVENESS ANALYSES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1565. | 0.8 | 1 |
| 17 | Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 123. | 1.9 | 21 |
| 18 | Health-Related Quality Of Life (Hrqol) Measures In Autosomal Dominant Polycystic Kidney Disease (Adpkd). <i>Value in Health</i> , 2015, 18, A512. | 0.3 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. <i>American Journal of Kidney Diseases</i> , 2015, 65, 833-841. | 1.9 | 68 |
| 20 | Psychometric analyses of patient-reported outcome instruments for autosomal dominant polycystic kidney disease. <i>Value in Health</i> , 2013, 16, A183. | 0.3 | 1 |
| 21 | Economic burden and resource use associated with autosomal dominant polycystic kidney disease among a medicare population. <i>Value in Health</i> , 2013, 16, A181. | 0.3 | 0 |
| 22 | Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. <i>Kidney International</i> , 2013, 84, 1278-1286. | 5.2 | 72 |
| 23 | PUK18 THE IMPACT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) ON PATIENTS' HEALTH RELATED QUALITY OF LIFE (HRQOL): DEVELOPMENT OF A CONCEPTUAL FRAMEWORK. <i>Value in Health</i> , 2011, 14, A77. | 0.3 | 0 |